Algert Global’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Algert Global’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13,013	Closed	-$41K	–	418
2018 Q1	$41K	Sell	13,013 -51,976	-80%	-$143K	0.01%	323
2017 Q4	$266K	Buy	+64,989	New	+$283K	0.06%	270

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Algert Global's OMED Position: Q2 2018 in Review

Algert Global sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2018, closing a stake of 13,013 shares — an estimated $41K sold.

Algert Global first reported a position in OMED in Q4 2017 and held it in 2 quarters. The position peaked at $266K in Q4 2017. 63 funds tracked by Wall St. Rank hold OMED as of Q2 2018.

Algert Global reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Algert Global sold 13,013 OncoMed Pharmaceuticals, Inc. shares in Q2 2018, an estimated $41K.
Algert Global first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
Algert Global's OncoMed Pharmaceuticals, Inc. position peaked at $266K in Q4 2017.
63 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2018.

Based on Algert Global's 13F filing for Q2 2018, filed 2 Aug 2018.